ITM develops therapies for cancer treatment. Bavaria is proud of this outstanding company, rooted in the research landscape of the Technical University of Munich, and a driver of technological progress since its foundation. With radiopharmaceuticals, ITM advances a technology that improves lives and brings hope worldwide. Bavaria champions progress through innovation. With unerring commitment, we stand by companies such as ITM and the radiopharmaceutical industry because they truly make a difference.

ITM is power! Our outstanding employees, passionate about our mission, contribute to achieving our company goals knowing that it’s about providing therapies for seriously ill patients.
Thanks to our successful funding rounds, we have laid a strong foundation for ITM’s growth and can now invest in our pipeline development and the expansion of our leading market position in the radioisotope business. Together, we are excited to finance future milestones, such as the market launch of therapeutics and diagnostics, thereby strengthening ITM’s strong position in the field of Radiopharmaceutical Therapy (RPT).

Our long-standing collaboration with ITM is characterized by outstanding scientific and clinical cooperation. Together, we have made significant advancements in radionuclide therapy for our patients thanks to innovative clinical and preclinical research. The continuous exchange of knowledge and expertise reinforces our partnership with ITM, and we look forward to jointly developing new innovative therapies in the future.

I am part of a united team of professionals working together to provide the very best care for the patients. We share the same goals, the same hopes, the same drive. We perform as a supportive, collaborative community, all interlocked to bring the best treatments to market. We talk with each other, support each other, learn from each other. Everyone’s door is open, everyone has something to teach, and everyone has something to learn. That is what I love about ITM – we are together.

The collaboration between the Technical University of Munich and ITM is built on a foundation of trust and the joint pursuit of innovation. Together, ITM and the Technical University of Munich are poised to further enhance their leadership in nuclear medicine. We anticipate a promising future marked by groundbreaking breakthroughs in the field of personalized medicine.

ITM, magic words for me. Not only because of my great colleagues, who are more of less like friends, but also because of:
• Great research
• Great pipeline
• Great products
Therefore…I am ITM

Some 20 years ago the Neutron Research Source Heinz Maier-Leibnitz (FRM II) produced its first neutrons. To enable transfers to industrial and medical applications, the Industrial Application Center (IAZ) was erected and ITM produced innovative radioisotopes for cancer therapy here for the first time. Today, ITM is a world leader in radiopharmacy and I am proud of having paved a small cobblestone on the way to 20 years ITM, what a success!

I remember my first congresses where everyone came together, even C-level were there, helping out. It was a powerful reminder that at ITM, no one is too important to pitch in. Today still, there is a spirit of camaraderie when the team comes together at the larger congresses. Whenever issues arise – everyone join forces to find a solution. These experiences have taught me the true spirit of ITM – perseverance, teamwork.

ITM’s consistent pipeline development is crucial for advancing radiopharmaceuticals and treating cancer patients. PSI will leverage its expertise and state-of-the-art research facilities to further strengthen ITM’s leading position in this.

Nuclear Medicine, specifically the area of theranostics, is playing an increasingly important role in patient care. I am grateful that ITM is at the forefront of this modality and that working here allows me an opportunity to help raise awareness regarding its ability to provide early diagnosis for patients and customized treatment options for healthcare professionals.

ITM, the company in its journey of “PATIENTS FIRST”, has moved beyond “maybe” to “here it is”. And contributes immensely to patient care and disease management in its endeavor of healing the world with its solutions. 

The long-standing collaboration with ITM is of great importance to my research group. Together, we developed a novel PSMA radioligand that is currently being investigated in a Phase I clinical trial. It is particularly motivating to pursue common goals with ITM to hopefully develop new therapies that benefit cancer patients in future.

 The covid pandemic led to our work becoming largely digitalized – MS Teams was rolled out in record time, and I’m impressed by what our IT department achieved! This flexibility has given me the perfect work-life balance.

We congratulate ITM on its impressive development over the last 20 years. From the initial joint Yttrium-90 experiments in 2005 in the wooden fume hoods of the old radiochemistry department, we quickly moved on to new synthesis processes for Lutetium-177. Increasing demand for advanced inert conveyor technology, larger columns and batches of separation materials catapulted us into the world of radiopharmacy. Our collaboration with ITM has always been exciting and productive, and today, ITM stands as not only our largest but also our most important customer.

It was fantastic to receive praise directly from the CEO for the team’s excellent work when we launched our first diagnostic agent on the market in Germany two years ago. Successes are celebrated together at ITM, while at the same time each individual employee is recognized and appreciated. That’s what sets ITM apart and I am really proud to be part of the ITM team. Together we can achieve a great deal.

In some respects, ITM can be seen as a product of FRM II, although it has since matured and gained independence. We are delighted with the longstanding 20-year partnership between FRM II, which supplies neutrons for the production of radioisotopes, and ITM, the production company that has effectively utilized these radioisotopes for medical purposes. Ad multos annos!

Congratulations to ITM, on 20 years of providing radioisotopes to patients around the world. I was fortunate to receive my first three treatment doses from ITM in 2009/10 without any delay. I also marveled while in Ghana as ITM delivered the first Lutetium-177 in Africa outside of South Africa showing commitment to patients worldwide.

What motivates me every day to come to the work is the next big thing happening in our industry. Radiopharmaceuticals is an ever changing and dynamic field which throws surprises at you every day at work. I am proud that ITM is a big player in the nuclear medicine industry and makes a big impact in offering innovative treatments to patients suffering from tough to treat cancers globally.

ITM has been crucial in the development of radiopharmaceutical therapies, advancing clinical trials and collaborations to address the growing need for precision oncology.

NTP Radioisotopes and ITM concluded a technology transfer agreement in 2012 that resulted in the reliable and sustainable supply of n.c.a. ¹⁷⁷Lu from NTP’s GMP certified facility. As NTP we are proud to be associated with ITM and we are committed to supporting them in every way to ensure the supply of quality product with capacities that will jointly satisfy the projected growth in demand.